Onset and duration of immunity against Babesia canis infection in dogs vaccinated with antigens from culture supernatants
- PMID: 16504401
- DOI: 10.1016/j.vetpar.2006.01.049
Onset and duration of immunity against Babesia canis infection in dogs vaccinated with antigens from culture supernatants
Abstract
It has previously been shown that dogs can be vaccinated against heterologous Babesia canis infection using a vaccine containing soluble parasite antigens (SPA) from in vitro cultures of B. canis and B. rossi that are adjuvanted with saponin. In the present study the onset and duration of immunity of vaccinated dogs were studied. Results showed that 3-26 weeks after initial vaccination, dogs effectively limit the level of SPA in plasma upon challenge infection, which was reflected in limited duration and extent of clinical manifestations. There was no statistically significant effect of vaccination on the parasite load in the circulation, which was determined from blood smears. It was further shown that the level of immunity of primary vaccinated dogs (priming and booster vaccination with a 6-week interval) and that of repeatedly vaccinated dogs (a single additional vaccination 6 months after primary vaccination) is comparable. From this study it is concluded that vaccination with this preparation induces protective immunity against clinical babesiosis from 3 weeks after booster vaccination onwards, and remains effective for a period of at least another 6 months. A single booster vaccination is sufficient to maintain immunity for at least another 6 months.
Similar articles
-
Immunity against Babesia rossi infection in dogs vaccinated with antigens from culture supernatants.Vet Parasitol. 2007 Mar 15;144(1-2):10-9. doi: 10.1016/j.vetpar.2006.09.026. Epub 2006 Oct 23. Vet Parasitol. 2007. PMID: 17056181
-
Vaccination of dogs against heterologous Babesia canis infection using antigens from culture supernatants.Vet Parasitol. 2001 Sep 12;100(1-2):75-86. doi: 10.1016/s0304-4017(01)00485-x. Vet Parasitol. 2001. PMID: 11522408
-
Vaccination against canine babesiosis.Trends Parasitol. 2005 Apr;21(4):179-84. doi: 10.1016/j.pt.2005.02.006. Trends Parasitol. 2005. PMID: 15780840 Review.
-
Vaccination against large Babesia species from dogs.Parassitologia. 2007 May;49 Suppl 1:13-7. Parassitologia. 2007. PMID: 17691601 Review.
-
Discovery of a recombinant Babesia canis supernatant antigen that protects dogs against virulent challenge infection.Vet Parasitol. 2018 Jan 15;249:21-29. doi: 10.1016/j.vetpar.2017.11.002. Epub 2017 Nov 6. Vet Parasitol. 2018. PMID: 29279083
Cited by
-
Molecular identification and antigenic characterization of a merozoite surface antigen and a secreted antigen of Babesia canis (BcMSA1 and BcSA1).Parasit Vectors. 2016 May 3;9:257. doi: 10.1186/s13071-016-1518-1. Parasit Vectors. 2016. PMID: 27141812 Free PMC article.
-
Successful vaccines for naturally occurring protozoal diseases of animals should guide human vaccine research. A review of protozoal vaccines and their designs.Parasitology. 2014 Apr;141(5):624-40. doi: 10.1017/S0031182013002060. Epub 2014 Jan 28. Parasitology. 2014. PMID: 24476952 Free PMC article. Review.
-
The immunopathology of canine vector-borne diseases.Parasit Vectors. 2011 Apr 13;4:48. doi: 10.1186/1756-3305-4-48. Parasit Vectors. 2011. PMID: 21489234 Free PMC article. Review.
-
[Comparative safety study of two commercialised vaccines against canine babesiosis induced by Babesia canis].Parasite. 2011 Nov;18(4):311-8. doi: 10.1051/parasite/2011184311. Parasite. 2011. PMID: 22091461 Free PMC article. French.
-
Impact of levels of parasitemia and antibodies, acute-phase proteins, as well as stays abroad on hematological and biochemical parameters in 342 dogs with acute Babesia canis infection.Parasit Vectors. 2025 Aug 15;18(1):347. doi: 10.1186/s13071-025-06997-4. Parasit Vectors. 2025. PMID: 40817086 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources